Multiple sclerosis trials in Belgium

In Belgium 19 Also abroad 506

19 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Where
Anderlecht, Gent, Pelt, Steenokkerzeel
Age
18 years to 60 years
People
705 worldwide
Run by
Zenas BioPharma (USA), LLC
See details and how to joinNCT07067463 · EU 2025-524316-11-00
Phase 3Taking people
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Where
Eeklo, Pelt, Sint-Lambrechts-Woluwe
Age
18 years to 60 years
People
990 worldwide
Run by
Zenas BioPharma (USA), LLC
See details and how to joinNCT07299019 · EU 2025-524322-18-00
No phaseNot yet taking people in Belgium
The Role of the FCRL5 Protein in the Pathophysiology of Multiple Sclerosis and Response to Treatment
Where
Brussels
Age
18 years to 80 years
People
90
Run by
Université Catholique de Louvain
See details and how to joinNCT07788573
Phase 3Taking people
Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis
Where
Gent, Pelt
Age
18 years to 64 years
People
386 worldwide
Run by
Sanofi-Aventis Recherche & Developpement
See details and how to join2023-504358-36-00 · EU 2023-504358-36-00
Phase 3Taking people
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Where
Brugge, Pelt
Age
40 years to 70 years
People
400 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06846281 · EU 2023-509275-17-00
Phase 3Taking people
A Randomized, Double-blind, Study to Demonstrate Pharmacokinetic Similarity, and Evaluate Safety, Immunogenicity, Pharmacodynamics and Clinical Effects between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis
Where
Roeselare
Age
18 years to 64 years
People
125 worldwide
Run by
Amgen Inc.
See details and how to join2024-512914-16-00 · EU 2024-512914-16-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Where
Bonheiden, Brussels, Leuven, Roeselare
Age
18 years to 65 years
People
1,275 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07225504
Phase 3Taking people
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
Where
Brugge, Gent, Kortrijk, Pelt, Sint-Lambrechts-Woluwe, Steenokkerzeel
Age
18 years to 60 years
People
160 worldwide
Run by
Sanofi
See details and how to joinNCT07325292 · EU 2026-525688-41-00
No phaseTaking people
At Home Use of Stimulation Suits for Managing MS Symptoms
Where
Steenokkerzeel
Age
18 years and over
People
70 worldwide
Run by
Daphne Kos
See details and how to joinNCT07202195
Phase 3Taking people
Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis
Where
Gent
Age
Up to 17 years
People
64 worldwide
Run by
Novartis Pharma AG
See details and how to join2024-511686-11-00 · EU 2024-511686-11-00
Phase 2Taking people
A Phase 2 Study of Obexelimab in Patients with Relapsing Multiple Sclerosis
Where
Pelt
Age
18 years to 64 years
People
93 worldwide
Run by
Zenas Biopharma (USA) LLC
See details and how to join2024-512707-40-00 · EU 2024-512707-40-00
Phase 3Taking people
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
Where
Anderlecht, Bonheiden, Leuven, Roeselare
Age
18 years and over
People
677 worldwide
Run by
Novartis Pharma AG
See details and how to join2025-521546-23-00 · EU 2025-521546-23-00
No phaseTaking people
Gait Adaptability in Persons With MS Having Mild Disability
Where
Diepenbeek
Age
18 years to 65 years
People
32
Run by
Hasselt University
See details and how to joinNCT07580820
No phaseTaking people
Cognitive-motor Telerehabilitation in MS
Where
Brussels, Melsbroek
Age
18 years to 65 years
People
90
Run by
Universitair Ziekenhuis Brussel
See details and how to joinNCT05355389
Phase 2Not yet taking people in Belgium
A Phase IIa Study of Vitamin D3 Tolerogenic Dendritic Cells (tolDC) for Multiple Sclerosis
Where
Edegem
Age
18 years to 65 years
People
14 worldwide
Run by
University Hospital, Antwerp
See details and how to joinNCT07020715 · EU 2025-522040-40-01
No phaseTaking people
Measurement Properties of the Walking Adaptability Ladder Test and Foot Tap Test in Multiple Sclerosis
Where
Diepenbeek
Age
18 years to 65 years
People
100 worldwide
Run by
Hasselt University
See details and how to joinNCT07505355
No phaseTaking people
Prognostic Value of Cerebrospinal Fluid Immunoglobulin Free Light Chains in Patients With Multiple Sclerosis
Where
Brussels
Age
18 years and over
People
100
Run by
Francis Corazza
See details and how to joinNCT05072691
No phaseTaking people
A Specialized Diet for Multiple Sclerosis
Where
Diepenbeek
Age
30 years to 65 years
People
100
Run by
Jerome J. A. Hendriks
See details and how to joinNCT07033975
No phaseNot yet taking people in Belgium
Transcranial Electrical Stimulation in Multiple Sclerosis
Where
Brussels, Melsbroek
Age
18 years and over
People
100
Run by
Universitair Ziekenhuis Brussel
See details and how to joinNCT06966128